同源重组缺陷生物标志物对接受辅助多柔比星和环磷酰胺治疗的三阴性乳腺癌患者结局的影响(SWOG S9313)
该研究基于SWOG S9313试验中425例三阴性乳腺癌患者,评估同源重组缺陷(HRD)状态和BRCA1启动子甲基化(PM)的预后价值。HRD阳性定义为肿瘤BRCA1/2有害突变或HRD评分≥42。结果显示HRD阳性与更好的无病生存(DFS)相关(HR 0.72,95%CI 0.51-1.00,P=0.049),HRD状态可能识别从AC方案化疗中获益更大的TNBC患者。
要点
- HRD阳性见于67%的TNBC患者,与更好的DFS显著相关。
- 在tBRCA阴性患者中,高HRD评分(≥42)与更好的DFS和OS相关。
- BRCA1启动子甲基化与DFS的关联未达统计学显著性。
核心结论
- HRD阳性在接受辅助AC化疗的TNBC患者中常见,并与更好的DFS相关。
- HRD状态可能识别从AC方案化疗中获益更大的TNBC患者,需前瞻性研究进一步评估。
研究设计与样本
- 从SWOG S9313试验中识别425例TNBC患者,进行HRD评分、肿瘤BRCA1/2测序和BRCA1启动子甲基化检测。
- HRD阳性定义为肿瘤BRCA1/2有害突变或HRD评分≥42。
- 采用Cox回归模型分析标志物对DFS和OS的预后价值,调整治疗分配和淋巴结状态。
主要发现
- HRD状态在89%(379/425)的病例中确定,其中67%为HRD阳性(27%有tBRCA突变,40%为tBRCA阴性但HRD评分≥42)。
- HRD阳性与更好的DFS相关(HR 0.72;95%CI 0.51-1.00;P=0.049),OS有改善趋势但未达显著性(HR 0.71;95%CI 0.48-1.03;P=0.073)。
- 在tBRCA阴性患者(n=274)中,高HRD评分(≥42)与更好的DFS(HR 0.64;95%CI 0.43-0.94;P=0.023)和OS(HR 0.65;95%CI 0.42-1.00;P=0.049)相关。
- BRCA1启动子甲基化在32%的病例中检测到,其DFS风险比与HRD相似但未达统计学显著性(HR 0.79;95%CI 0.54-1.17;P=0.25)。
关键数值与推荐
- HRD阳性定义:肿瘤BRCA1/2有害突变或HRD评分≥42。
- HRD阳性与DFS的HR为0.72(95%CI 0.51-1.00;P=0.049)。
- tBRCA阴性患者中HRD评分≥42与DFS的HR为0.64(95%CI 0.43-0.94;P=0.023),与OS的HR为0.65(95%CI 0.42-1.00;P=0.049)。
临床怎么用
- HRD状态可能用于识别从辅助AC方案化疗中获益更大的TNBC患者。
- HRD检测有助于TNBC患者的预后分层。
局限性
- HRD状态仅在89%的病例中可评估。
- BRCA1启动子甲基化仅在82%的病例中成功评估。
- 回顾性分析,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homologous recombination deficiency (HRD)-causing alterations have been reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD alterations might be more sensitive to anthracycline plus cyclophosphamide-based chemotherapy and report on HRD status and BRCA1 promoter methylation (PM) as prognostic markers in TNBC patients treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG9313. PATIENTS AND METHODS: In total, 425 TNBC patients were identified from S9313. HRD score, tumor BRCA1/2 sequencing, and BRCA1 PM were carried out on DNA isolated from formalin-fixed paraffin-embedded tissue. Positive HRD status was defined as either a deleterious tumor BRCA1/2 (tBRCA) mutation or a pre-defined HRD score ≥42. Markers were tested for prognostic value on disease-free survival (DFS) and overall survival (OS) using Cox regression models adjusted for treatment assignment and nodal status. RESULTS: HRD status was determined in 89% (379/425) of cases. Of these, 67% were HRD positive (27% with tBRCA mutation, 40% tBRCA-negative but HRD score ≥42). HRD-positive status was associated with a better DFS [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.51-1.00; P = 0.049] and non-significant trend toward better OS (HR = 0.71; 95% CI 0.48-1.03; P = 0.073). High HRD score (≥42) in tBRCA-negative patients (n = 274) was also associated with better DFS (HR = 0.64; 95% CI 0.43-0.94; P = 0.023) and OS (HR = 0.65; 95% CI 0.42-1.00; P = 0.049). BRCA1 PM was evaluated successfully in 82% (348/425) and detected in 32% of cases. The DFS HR for BRCA1 PM was similar to that for HRD but did not reach statistical significance (HR = 0.79; 95% CI 0.54-1.17; P = 0.25). CONCLUSIONS: HRD positivity was observed in two-thirds of TNBC patients receiving adjuvant AC and was associated with better DFS. HRD status may identify TNBC patients who receive greater benefit from AC-based chemotherapy and should be evaluated further in prospective studies. CLINICAL TRIALS NUMBER: Int0137 (The trial pre-dates Clinicaltrial.Gov website establishment).
引用
- Sharma P, Barlow WE, Godwin AK, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol. 2018. PMID: 29293876. doi:10.1093/annonc/mdx821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。